EXHIBIT 99.1

                     GENOMIC SOLUTIONS' STOCKHOLDERS APPROVE
                   ACQUISITION OF CARTESIAN TECHNOLOGIES, INC.

 -  STRENGTHENS POSITION AS LEADING GLOBAL PROVIDER OF DRUG DISCOVERY TECHNOLOGY

 -  2002 REVENUE PROJECTED AT $30 - 36 MILLION

 -  ENHANCED PRODUCT PORTFOLIO WITH ADDITION OF  HIGH-THROUGHPUT SCREENING

Ann Arbor, MI, December 18, 2001 - Genomic Solutions Inc. (Nasdaq: GNSL)
announced today that its stockholders have voted in favor of the Genomic
Solutions' acquisition of Irvine, California-based Cartesian Technologies, Inc.
The acquisition extends Genomic Solutions' capabilities into high-throughput
screening and strengthens the company's position as a global provider of
comprehensive DNA analysis and drug discovery solutions.

"We believe the acquisition of Cartesian will create greater stockholder value,
with enhanced potential for earnings and revenue growth. The goal of the
corporation and all its employees is to achieve positive earnings before
interest, taxes, depreciation and amortization ("EBITDA") in early 2002, and
remain a profitable enterprise, thereafter," according to Jeffrey S. Williams,
President and CEO of Genomic Solutions. "We are focusing on EBITDA as we feel it
best reflects our operating performance since all our net income to be reported
going forward will include amortization expense associated with the Cartesian
intangibles."

For 2002, Genomic Solutions forecasts revenues of between $30 million to $36
million and EBITDA of between $800,000 and $2.8 million. The company expects to
achieve breakeven EBITDA in the first quarter of fiscal 2002 and positive EBITDA
in the second quarter of fiscal 2002.

"With the acquisition of Cartesian Technologies, Genomic Solutions is well
positioned to capitalize upon our combined resources, technology, products and
expertise to create a company with expanded market depth and product offerings,
" stated Williams. "The integration process, which began after the signing of
the definitive agreement, is progressing smoothly and we are successfully
meeting our milestones."

According to Thomas C. Tisone, Ph.D., President of Cartesian Technologies, Inc.,
"Customers will now have a broader technology choice from one supplier resulting
in better integration of instrumentation and service, which naturally leads to
higher throughput." Dr. Tisone will remain with Genomic Solutions and will have
responsibility for the Company's Irvine-based product development and supply
organization.

ABOUT GENOMIC SOLUTIONS INC.

The company designs, develops, manufactures, markets and sells instruments,
software, and consumables used to determine the activity level of genes and to
isolate, identify and characterize proteins. The company's products and systems,
marketed under the GeneTAC(TM) Biochip System, Investigator (TM) Proteomic
System and GeneMAP(TM) preprinted arrays brands, enable researchers to perform
complex, high volume experiments at a lower cost and in less time than
traditional techniques. As a result, Genomic Solutions products and systems
facilitate more rapid and less expensive drug discovery.

SPECIAL NOTE

This press release contains "forward-looking" statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. For this purpose, any statements contained in this press
release that relate to prospective events or developments are deemed to be
forward-looking statements. Words such as "believes," "forecasts,"
"anticipates," "plans," "expects," "will" and similar expressions are intended
to identify forward-looking statements. While we may elect to update
forward-looking statements in the future, we specifically disclaim any
obligation to do so, even if our estimates change, and you should not rely on
these forward-looking statements as representing our views as of any date
subsequent to the date of this press release. The following important factors
and uncertainties, among others, could cause actual results to differ materially
from those described in these forward-looking statements: a downturn in our
customers' markets or in general economic conditions; our failure to introduce
new products in a timely manner; economic, political and other risks associated
with international sales and operations; difficulties integrating technologies,
operations and personnel of recent acquisitions; competition from third parties,
including pricing pressure; governmental regulation; research and development
progress, and our level of debt and the possible incurrence of additional debt
in the future. These and other important factors that may affect our actual
results are discussed in detail in the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2000 and in our other
filings with the Securities and Exchange Commission.

For more information, contact Genomic Solutions at
corporatecommunications@genomicsolutions.com or visit the company's Web site,
www.genomicsolutions.com.

CONTACTS:

INVESTORS
Steven J. Richvalsky
Executive Vice President,
and Chief Financial Officer
steve@genomicsolutions.com

MEDIA
Kathleen M. Murphy
Vice President, Corporate Communications
kmurphy@genomicsolutions.com

Both of Genomic Solutions Inc.
Telephone: (734) 975-4800